Down syndrome candidate region 1 (
Introduction
Down syndrome candidate region 1 (DSCR1) is one of more than 50 genes present in that portion of chromosome 21 that is duplicated in trisomy 21, the chromosomal abnormality responsible for Down syndrome (1) (2) (3) . DSCR1 is identical to MCIP1 (modulatory calcineurin -interacting protein; ref. 4) . It is homologous to Adapt78, an oxidant stress-inducible gene in hamsters (5) (6) (7) and also to Rcn1/nebula in Drosophila (8) . Down syndrome is a major cause of mental retardation and is also associated with various cardiac and gastrointestinal anomalies, immune system defects, and Alzheimer's disease. Of relevance to cancer, patients with Down syndrome have an increased risk of certain malignancies (leukemia, germ cell tumors) but an extremely low incidence of many solid tumors, particularly breast cancer (9, 10) . On the other hand, clinically aggressive ovarian carcinomas often have trisomy of chromosome 21, whereas certain other solid tumors have deletions of this chromosome. Together, these and other data suggest that genes such as DSCR1 that are duplicated in Down syndrome may play important roles in tumorigenesis (11, 12) .
Interest in DSCR1 has recently been sparked by several reports indicating that it is up-regulated in cultured vascular endothelial cells by vascular endothelial growth factor (VEGF-A 165 ), and furthermore, that it provides a negative feedback loop that inhibits VEGF-A 165 -induced angiogenesis (13) (14) (15) (16) . However, these conclusions were based on the study of only one DSCR1 isoform, isoform 4 (DSCR1-4). The DSCR1 gene is comprised of seven exons, the first four of which can serve as start sites that then combine with exons 5 to 7 to produce four different mRNA transcripts (2, 17) . Exon 1 was originally thought to encode a 29 -amino acid peptide (DSCR1-1; refs. 2, 17) , but later studies by Genesca et al. (18) revealed a start site further upstream that encoded an 84 -amino acid peptide (DSCR1-1L). Exon 2 is probably not translated into protein because it lacks a methionine start site. Exon 3 encodes only three amino acids (2, 17) . Exon 4, under the control of a different promoter from that regulating isoforms 1 to 3 (2, 17) , encodes a 29 -amino acid peptide that initiates a fourth DSCR1 isoform. Several DSCR1 isoforms have different expression patterns and likely different functions and regulatory mechanisms (2, 17) . All four isoforms are expressed in heart and skeletal muscle (2, 17) . Isoform 1 has also been detected in brain, whereas isoform 4 has been detected in placenta and kidney (2, 17) . DSCR1-1L has been found to play a protective role against cell stress (5) (6) (7) . In addition to inhibiting angiogenesis (13) (14) (15) (16) , DSCR1-4 plays an inhibitory role in cardiac and skeletal muscle hypertrophy (19) (20) (21) .
The present study was undertaken to determine whether other DSCR1 isoforms had roles in angiogenesis analogous to that of DSCR1-4. We report here that DSCR1-1L, like DSCR1-4, is upregulated by VEGF-A 165 in cultured endothelial cells and also in several types of pathologic angiogenesis in vivo. DSCR1-1L is also expressed in the microvasculature of at least some human ovarian cancers, but not in the tumor cells themselves nor in the microvessels of normal ovary. Of particular interest, the effects of DSCR1-1L in angiogenesis are antithetical to those of DSCR1-4. Using a novel modification of the standard Matrigel assay, we found that overexpression of DSCR1-1L promoted endothelial cell proliferation in vitro and angiogenesis in vivo, whereas a DSCR1-1L -specific small interfering RNA (siRNA) had opposite effects. Furthermore, whereas DSCR1-4 binds to calcineurin and prevents it from activating the transcription factor NFAT, DSCR1-1L activates the calcineurin-NFAT pathway. Taken together, our data indicate that DSCR1 isoforms 1 and 4 have opposing stimulatory and inhibitory effects on VEGF-A 164/5 -induced angiogenesis.
Results

Up-Regulation of DSCR1-1L In vitro and In vivo
In agreement with recent reports (13-15), we found that VEGF-A 165 strongly up-regulated DSCR1 expression in human umbilical vein endothelial cells (HUVEC) as determined by DNA microarrays and quantitative real-time reverse transcription-PCR (RT-PCR). Maximum DSCR1 mRNA expression appeared 1 hour after serum-starved HUVEC were stimulated with 10 ng/mL of VEGF-A 165 (data not shown). We then set out to determine whether DSCR1 isoforms 1 and 4 were regulated differentially by VEGF-A 165 in vascular endothelium. Because isoform-specific internal probes could not be developed for quantitative real-time reverse transcription-PCR, we used semiquantitative RT-PCR to evaluate the expression of DSCR1 isoforms. Using NH 2 -terminal-specific primers (17), we found that VEGF-A 165 up-regulated both DSCR1-1L and DSCR1-4 mRNAs in serum-starved HUVEC and human microdermal vascular endothelial cells (HMDVEC; Fig. 1A ). Immunoblots revealed that DSCR1-1L protein was up-regulated in HUVEC in a time-dependent fashion by VEGF-A 165 , but to a lesser extent than DSCR1-4 (Fig. 1B) . Similar results were obtained with HMDVEC cells (data not shown).
To evaluate the role of DSCR1 in vascular endothelium in vivo, we made use of an established angiogenesis assay in which an adenoviral vector expressing mVEGF-A 164 (mouse equivalent of human VEGF-A 165 ) was injected into nude mouse ear skin; an adenoviral vector expressing LacZ, that did not induce angiogenesis, served as a control (22) . Ears were harvested at different stages of the angiogenic response and prepared for immunoblot assays. Using an antibody that recognized all mouse DSCR1 isoforms, we found that DSCR1 protein was highly up-regulated as angiogenesis developed, reaching a peak on day 3 ( Fig. 2A) . DSCR1 expression was not stimulated by Ad-LacZ. DSCR1 protein was also up-regulated in the angiogenic response that was induced in the mesenteries of nude mice bearing ascites mouse ovarian tumor (MOT; Fig. 2A) .
We next determined which DSCR1 isoforms were upregulated in Ad-mVEGF-A 164 -induced angiogenesis, using semiquantitative RT-PCR (Fig. 2B) . We found that both DSCR1-1L and DSCR1-4 RNAs were induced by AdmVEGF-A 164 , peaking at 12 hours after ear injection (lane 1); Ad-LacZ did not stimulate expression of either isoform (lane 2). DSCR1-1L and DSCR1-4 were also both up-regulated in the mesenteries of mice bearing MOT ascites tumors (lane 3). However, MOT cells themselves did not express detectable amounts of DSCR1-1L and only trace amounts of DSCR1-4 (lane 4).
Specific antibodies are available against human DSCR1 isoforms 1 and 4, and we used these to perform immunohistochemistry on five cases of human ovarian adenocarcinoma. Both DSCR1-1L and DSCR1-4 were selectively expressed in the tumor vascular endothelium but not in the tumor cells nor in the vessels of adjacent normal ovarian tissue (Fig. 2C) . Together, these data indicate that both DSCR1-1L and DSCR1-4 are highly expressed in the newly formed vessels of several types of pathologic angiogenesis in mice and in at least some human ovarian cancers.
Transfection of HUVEC with Full-Length DSCR1 Isoforms or with Isoform-Specific siRNAs
We used two approaches to investigate the effects of DSCR1 isoforms on vascular endothelium. First, we used RT-PCR to clone full-length DSCR1-1L, DSCR1-3, and DSCR1-4 cDNAs from total RNA that we isolated from HUVEC that had been treated for 1 hour with VEGF-A 165 . After confirming their identity by DNA sequencing, we fused the Flag sequence inframe to the NH 2 terminus of each and subcloned the products into a retroviral expression vector that gave nearly 100% Up-regulation of DSCR1 isoforms 1L and 4 in HUVEC and HMDVEC stimulated with VEGF-A 165 as determined by semiquantitative RT-PCR using isoform-specific primers. In the case of DSCR1-4, two bands are apparent; only the lower of these (arrow ) is authentic, as was proved by DNA sequencing; the upper band reflects a lack of PCR primer specificity. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) serves as an internal loading control. B. Immunoblot of DSCR1 isoforms 1L and 4 in HUVEC that were serum-starved (0.1% fetal bovine serum) for 24 hours and stimulated with 10 ng/mL of VEGF-A 165 for 1, 2, 4, and 6 hours.
infection yields in HUVEC (23) . Cell extracts from HUVEC transduced with Flag-fused versions of DSCR1-1L (FD1L), DSCR1-3 (FD3), DSCR1-4 (FD4), and LacZ (FLacZ), were immunoprecipitated with an antibody against Flag and immunoblotted with an antibody reactive against all human DSCR1 isoforms. Figure 3A shows that FD1L, FD3, FD4, and Lac Z proteins were all expressed in HUVEC.
As a second approach, we designed siRNAs that specifically targeted the NH 2 -terminal sequence of DSCR1-1L (D1Si) and DSCR1-4 (D4Si), as well as a control siRNA (Neg-Si, a scrambled version of the D4Si sequence). Cell extracts from HUVEC that had been infected with retroviruses expressing these siRNAs were immunoblotted with antibodies specific for DSCR1-1L and DSCR1-4. D1Si and D4Si strongly and specifically inhibited the expression of DSCR1-1 and DSCR1-4, respectively, whereas Neg-Si had no effect on either (Fig. 3B) . On the other hand, transduction with the DSCR1-4-specific siRNA D4Si significantly enhanced thymidine incorporation both in the absence and presence of VEGF-A 165 (lane 13 versus lanes 1 or 3; lane 14 versus lanes 2 or 4, both P < 0.001). Control Neg-Si had no effect on thymidine incorporation in HUVEC with or without VEGF-A 165 stimulation (lane 15 versus lanes 1 or 3; lane 16 versus lanes 2 or 4, both P > 0.05). Transduction with FD3 also had no effect on thymidine incorporation without VEGF-A 165 (lane 9 versus lanes 1 or 3, P > 0.05) or following its addition (lane 10 versus lanes 2 or 4, P > 0.05).
We next tested whether DSCR1 isoform-specific siRNAs had effects on KDR (VEGF receptor 2) expression or on VEGF-A 165 -induced KDR phosphorylation. Serum-starved HUVEC that had been transduced with D1Si, D4Si, or with control Neg-Si were stimulated with 10 ng/mL of VEGF-A 165 for 2 minutes. Cell extracts were immunoprecipitated with an antibody against KDR and immunoblotted with an antibody against phosphorylated tyrosine (PY20). Neither D1Si nor D4Si had any effect on VEGF-A 165 -stimulated KDR phosphorylation ( Supplementary Fig. S1 , top). The blot was then stripped and reprobed with an antibody against KDR. The expression of KDR was also not affected by D1Si or D4Si transduction ( Supplementary Fig. S1 , bottom). These data indicate that, as anticipated, the effects of D1Si and D4Si on VEGF-A 165 -stimulated HUVEC proliferation are not due to the inhibition of KDR expression or phosphorylation.
Effects of DSCR1 Isoforms on VEGF-A-Induced Angiogenesis In vivo
In order to elucidate the mechanisms of angiogenesis, it would be desirable to modulate the expression of individual vascular genes in vivo using the gene overexpression and silencing approaches that have proved to be so powerful in vitro. Recently, a novel system has been developed that allowed us to introduce DSCR1 isoform -specific cDNAs or siRNAs into endothelial cells in vivo (25) (26) (27) The angiogenic response that developed after the implantation of Matrigel plugs containing various cell mixtures was evaluated on day 3 (Fig. 4A) . Angiogenesis was assessed by macroscopy (top) and by histology and immunohistochemistry for the endothelial cell marker CD31 (bottom). Matrigel plugs containing only PT67 cells packaging LacZ-expressing retroviruses (PT67/LacZ cells) induced minimal angiogenesis (lane 1). However, strong angiogenesis with typical ''mother'' vessels was induced in plugs containing SK-MEL/VEGF cells, whether alone or combined with PT67/LacZ cells (lanes 2 and 3). Mother vessels are enlarged, thin-walled, pericyte-poor vessels that are the first new vessel type induced by VEGF-A 164 in vivo (22) . The angiogenic response and mother vessel formation were strikingly depressed by the inclusion of PT67/ D1Si cells (lane 4) but were not affected by the inclusion of either PT67/D4Si or PT67/Neg-Si cells (lanes 5 and 6). However, the inclusion of PT67/FD4 cells completely inhibited VEGF-Ainduced angiogenesis and mother vessel formation (lane 7), whereas overexpression of FD1L was associated with strong angiogenesis (lane 8). The inclusion of PT67/FD3 cells had no effect on the angiogenic response induced by SKMEL/VEGF cells (lane 9). Immunostaining with antibody against DSCR1 indicated that DSCR1 was induced in the vessel structure ( Supplementary Fig. S2 , a, arrows), which was almost completely inhibited by D1Si or D4Si ( Supplementary Fig. S2 , b and c, arrows), but was not affected by SiNeg ( Supplementary Fig. S2 , d, arrow). In situ hybridization also confirmed the knockdown of DSCR1 expression by D1Si and D4Si (data not shown). Furthermore, in situ hybridization indicated that the expression levels of VEGF-A 165 were similar in Matrigels containing these different cell mixtures (see ref. 25); also, transfection of SKMEL and PT67 cells with FD1L, FD4, and etc., has no effect on these cells' proliferation. Therefore, the results obtained cannot be attributed to the effects of VEGF-A expression.
We next tested whether the overexpression of DSCR1-1L could induce angiogenesis in the absence of VEGF-A 165 (Fig. 4B) . Matrigels containing only PT67/FD1L cells were able to induce angiogenesis and mother vessel formation (lane 2) to an extent similar to that induced by VEGF-A 165 -expressing cells (lane 1). However, Matrigels containing only PT67/FD3 did not induce angiogenesis (lane 3). When DSCR1-4 expressing FD4 cells were included in Matrigels along with DSCR1-1L expressing FD1L cells in the absence of SKMEL/VEGF cells, the angiogenic response expected from FD1L cells was abrogated (lane 4). Immunostaining and in situ hybridization confirmed the similar expression of DSCR1-1, DSCR1-3, and DSCR1-4 with an antibody against Flag (Supplementary Fig. S3 ; data not shown).
To confirm that the angiogenesis induced by PT67/FD1L was not due to the induction of VEGF-A expression, we made HUVEC transduced with isoform-specific siRNAs or with a scrambled DSCR1-4 siRNA (Neg-Si) were immunoblotted with antibodies specific for hDSCR1-1L and hDSCR1-4. D1Si specifically knocked down the expression of DSCR1-1L but had no effect on DSCR1-4. D4Si specifically knocked down the expression of DSCR1-4 but had no effect on DSCR1-1L. Neg-Si had no effect on either DSCR1-1L or DSCR1-4 expression. C. and that DSCR1-4 inhibits that response.
Quantification of the Effects of DSCR1 Isoforms and siRNAs on Angiogenesis
We next used the intravascular plasma volume of Matrigel plug -associated blood vessels as a novel measure to quantitate the angiogenic response induced by VEGF-A 165 and DSCR1 isoforms (25) . Intravascular plasma volume is an appropriate measure as enlarged mother vessels are a signature property of the early angiogenic response to VEGF-A (22, 29). Evan's blue dye was injected i.v. into mice 3 days after implanting Matrigel plugs containing various cell mixtures. Evan's blue dye binds to plasma proteins, and therefore, the amount of plasma within the Matrigel-associated vasculature can be calculated from simultaneous measurements of dye concentration in peripheral blood plasma. Matrigel plugs were harvested 5 minutes after i.v. dye injection, when blood vessels were filled with dye-plasma protein complexes, but before there was time for significant extravasation.
In Matrigel plugs containing VEGF-A 165 -expressing SKMEL/VEGF cells (alone or with PT67/LacZ cells), intravascular plasma volume as measured by Evan's blue dye accumulation increased >2-fold above baseline levels (Fig. 4C,  lanes 2 or 3 versus lane 1, P < 0.001) . The presence of PT67/D1Si cells expressing DSCR1-1 siRNA strikingly blocked the angiogenic response expected from SKMEL/VEGF cells (Fig. 4C , lane 4 versus lanes 2 and 3, P < 0.001). However, cells expressing DSCR1-4 siRNA (D4Si) or control siRNA (Neg-Si) had no effect on the angiogenic response induced by SKMEL/VEGF cells (Fig. 4C , lanes 5 and 6 versus lanes 2 or 3, P > 0.05). The inclusion of PT67/FD1L cells expressing DSCR1-1L or PT67/FD3 cells expressing DSCR1-3 also had no effect (Fig. 4C , lanes 7 and 8 versus lanes 2 or 3, P > 0.05). However, when PT67/FD4 cells expressing DSCR1-4 were incorporated in Matrigel plugs, the increased dye accumulation expected from SKMEL/VEGF cells was strongly inhibited (Fig. 4C , lane 9 versus lanes 2 or 3, P < 0.001). In the absence of SKMEL/VEGF cells, dye accumulation in Matrigel plugs containing PT67/FD1L cells was similar to that of Matrigels containing SKMEL/VEGF cells (Fig. 4C , lane 10 versus lane 2, P > 0.05). However, dye accumulation in Matrigels containing PT67/FD3 or PT67/FD4 cells was similar to that of Matrigels containing PT67/LacZ cells (Fig. 4C, lanes 11 or 12, versus lane 1, P > 0.05). The quantitative measurements of vascular plasma volumes presented in Fig. 4C therefore confirm the qualitative measures of angiogenesis presented in Fig. 4A and B.
Effects of DSCR1-1L and DSCR1-4 on the Calcineurin-NFAT Pathway
The COOH-terminal domain of DSCR1 has been shown to bind to calcineurin and to inhibit its activity, preventing the activation (dephosphorylation) of NFAT and its translocation to the nucleus (13-16, 30 ). However, a recent report has shown that phosphorylation of RCN1, the Drosophila orthologue of MCIP1/DSCR1, has an opposite effect, enhancing calcineurin activity (31) . These results suggested to us that different DSCR1 isoforms might be responsible for these opposite effects of DSCR1 on calcineurin binding and activation. To test this possibility, we investigated the effects of DSCR1-1L on the calcineurin pathway. We included cyclosporin A, an inhibitor of calcineurin, in Matrigel plugs containing FD1L cells that expressed DSCR1-1L; cyclosporin A was also injected i.p. daily. As shown in Fig. 4D , cyclosporin A strongly inhibited DSCR1-1L-induced angiogenesis, suggesting that DSCR1-1L regulated angiogenesis through calcineurin activation.
We next tested the effects of DSCR1 isoforms and their specific siRNAs on NFATc1-dependent reporter expression. NFATc1 is the only NFAT protein that is activated by VEGF in endothelial cells (32) . HUVEC transduced with DSCR1 isoform cDNAs or their isoform-specific siRNAs were transfected with a NFATc1-targeted promoter-luciferase plasmid and an internal control luciferase plasmid, and then stimulated with VEGF-A 165 for 6 hours. Luciferase activity was measured and normalized to the control luciferase activity for equal transfection efficiency. As shown in 12 versus  lanes 1 and 2, respectively, although the effects were not statistically significant, P > 0.05). Control siRNA (Neg-Si) had no effect on NFATc1 activity in the presence or absence of VEGF-A 165 (lane 13 versus lane 1 and lane 14 versus lane 2, both P > 0.05). We further tested whether the overexpression of DSCR1-1L induced DSCR1-4 expression. Cellular extracts from cells transduced with FD4, FLacZ, and FD1L were immunoblotted with an antibody against DSCR1. Figure 5B clearly indicated that overexpression of DSCR1-1L induced the expression of DSCR1-4 (Fig. 5B) .
Discussion
Recent studies from several laboratories have shown that VEGF-A 165 up-regulates DSCR1-4, one of four proposed DSCR1 isoforms, in vascular endothelial cells. DSCR1-4 then triggers a negative feedback loop that quenches VEGF-A 165 -induced endothelial cell proliferation and tube formation in vitro and angiogenesis in vivo (13) (14) (15) (16) . We have confirmed and extended these findings but have also shown for the first time that another DSCR1 isoform, DSCR1-1L, plays an important proangiogenic role that is opposite to and opposes that of DSCR1-4. On the other hand, expression of a third DSCR1 isomer, DSCR1-3, apparently does not have a significant role in VEGF-A 165 -mediated angiogenesis (Figs. 3C, 4 , and 5). VEGF-A 165 up-regulated DSCR1-1L in HUVEC at both the mRNA and protein levels, although to a lesser extent than DSCR1-4 ( Fig. 1A and B) . In addition, both DSCR1-1L and DSCR1-4 were up-regulated in the angiogenic responses induced in vivo by a VEGF-A 164 -expressing adenovirus and by VEGF-A 164 -expressing MOT tumors (Fig. 2B) . Of importance, the MOT tumor cells did not themselves express DSCR1-1L detectably, and expressed only trace amounts of DSCR1-4. Because antibodies reactive with mouse DSCR1 in tissue sections are not available, we could not further localize DSCR1 in these models. However, both DSCR1-1L and DSCR1-4 were selectively localized to the microvessels supplying human ovarian cancers (Fig. 2C) .
Of considerable interest, DSCR1-1L and DSCR1-4 were found to have antithetical effects on the angiogenic response, both in vitro and in vivo. Consistent with earlier reports (13) (14) (15) (16) , overexpression of DSCR1-4 strikingly inhibited VEGF-A 165 -mediated 3 H-thymidine incorporation in cultured HUVEC, whereas a DSCR1-4-specific siRNA (D4Si) stimulated such incorporation in both the presence and absence of added VEGF-A 165 (Fig. 3C) . Similarly, PT67/FD4 cells strongly inhibited angiogenesis in Matrigel assays in vivo, whereas PT67/D4Si cells had an opposite, proangiogenic effect (Fig. 4) . In contrast, the overexpression of DSCR1-1L significantly increased 3 H-thymidine incorporation above control levels both in the presence and absence of added VEGF-A 165 , whereas VEGF-A 165 -mediated stimulation of thymidine incorporation was strikingly inhibited in HUVEC transduced with a DSCR1-1L-specific siRNA (Fig. 3C) . Also, PT67/FD1L cells overexpressing DSCR1-1L induced strong angiogenesis in the in vivo Matrigel assay in the presence or absence of a source of VEGF-A 165 , whereas the inclusion of PT67/D1Si cells expressing an DSCR1-1L-specific siRNA strongly inhibited VEGF-A 165 -induced angiogenesis (Fig. 4) . Taken together, these data indicate that, whereas DSCR1-4 provides a negative feedback loop, DSCR1-1L promotes and is actually required for VEGF-A 165 -mediated angiogenesis. Furthermore, mechanistic studies determined that isoform-specific DSCR1 siRNAs did not affect KDR expression or phosphorylation ( Supplementary Fig. S1 ) and that the proangiogenic effect of DSCR1-1L was not inhibited by SU1496, an inhibitor of VEGF receptor 2 (KDR), the receptor through which VEGF-A 165 mediates endothelial cell proliferation and angiogenesis ( Supplementary Fig. S4 ). Therefore, DSCR1-1L must be acting downstream of VEGF-A and its receptor.
The antiangiogenic activity of DSCR1-4 has been attributed to its suppression of the calcineurin-NFAT pathway (refs. 14, 16; Fig. 6 ). Calcineurin is a calcium-regulated, serine/threonine phosphatase that is activated by VEGF-A and other growth factors to dephosphorylate and thereby activate the transcription factor, NFAT (14) (15) (16) 33) . Activated NFAT translocates to the cell nucleus in which it acts cooperatively with other transcription factors to induce the expression of a large number of genes, including many that have roles in angiogenesis and inflammation. By binding to and inactivating calcineurin, DSCR1-4 reverses NFAT activation and shuts down the transcription of proangiogenic genes such as GM-CSF, Cox 2, IL-8, E-selectin, and tissue factor (13) (14) (15) (16) .
How do the proangiogenic effects of DSCR1-1L fit into this model? The calcineurin-NFAT axis is apparently involved because cyclosporin A, a calcineurin inhibitor, prevented PT67/ FD1L cells from inducing angiogenesis in Matrigel plugs (Fig. 4D) . Also, using a luciferase reporter assay, NFATc1 activity was increased in FD1L cells (HUVEC transfected with DSCR1-1L), either in the presence or absence of VEGF-A 165 , and VEGF-A 165 -mediated activity of NFATc1 was depressed when HUVEC were transfected with D1Si (Fig. 5A) . Furthermore, NFAT activation was strongly inhibited in FD4 cells that overexpressed DSCR1-4 (Fig. 5A) . In addition, experiments from Drosophila indicate that phosphorylation of RCN1, an orthologue of MCIP1/DSCR1, enhances calcineurin activity (34) ; these data support our findings that the DSCR1 gene can both inhibit and activate calcineurin.
Remaining to be elucidated is the signaling pathway by which VEGF-A 165 induces DSCR1-1L expression. Unlike DSCR1-4, DSCR1-1L is not likely to be induced through the calcineurin-NFAT pathway (13) (14) (15) (16) . Whereas the promoter regulating DSCR1-4 is found in the intron preceding exon 4 and contains NFAT binding sites (34) , the promoter regulating DSCR1-1L lies upstream of exon 1 and lacks NFAT binding sites (our unpublished data). Also remaining to be investigated are the mechanisms regulating the interplay between DSCR1-1L and DSCR1-4 signaling that determine whether angiogenesis is induced or inhibited. In the only experiment in which both of these isoforms were introduced into Matrigel (Fig. 4B, lane 4) , the net effect was inhibition of angiogenesis.
DSCR1-1L was overlooked in earlier studies of VEGF-A-mediated regulation of DSCR1 function, likely for technical reasons that may have included the source of cultured cells, differences in serum starvation conditions (0.5% versus 0.1% serum), plate coatings (fibronectin versus collagen), etc. This would not be the first time that apparently minor differences in tissue culture technique have profoundly affected VEGF-A 165 signaling. For example, plating HUVEC on collagen or fibronectin determined whether PLCg or phosphatidylinositol-3-kinase was required for VEGF-A 165 -stimulated HUVEC proliferation (23) . Also, DSCR1-1L is expressed at much lower levels than DSCR1-4 in HUVEC and HMDVEC and its expression at both mRNA and protein levels was less stimulated by VEGF-A 165 in these cultured cells (Fig. 1A and B) . Nonetheless, although undetectable in the microvasculature of several normal tissues, DSCR1-1L was strongly expressed in vivo in the angiogenic responses induced by Ad-mVEGF-A 164 and by mouse and human ovarian cancers (Fig. 2) .
In summary, DSCR1-1L and DSCR1-4 represent distinct isoforms of the same gene that are regulated by different promoters and that have opposite effects on VEGF-A 164/5 -induced angiogenesis. How these conflicting activities are balanced in tumor angiogenesis in vivo remains to be determined. The possibilities include differential promoter regulation, expression levels, timing of expression, interacting proteins, etc., questions we are now addressing. The expression of different DSCR1 isoforms by different types of tumors could explain the puzzling findings that, in patients with Down syndrome, the incidence of certain types of malignancy is increased, whereas that of others is decreased (9) (10) (11) (12) . In any event, DSCR1-1L should be considered as a possible target for the therapeutic regulation of pathologic angiogenesis. 
Materials and Methods
Materials
Rat anti-mCD31 antibody and mouse anti-hCD31 antibody were obtained from BD Biosciences (BD Biosciences, PharMingen, San Diego, CA) and Dako (Carpinteria, CA), respectively. Anti-KDR antibody and anti-phosphorylated tyrosine (p-PY20) were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Mouse monoclonal antibodies against human DSCR1 (all isoforms, hDSCR1), against specific human DSCR1 isoforms (hDSCR1-1, hDSCR1-3, and hDSCR1-4), and against mouse DSCR1 (all isoforms, mDSCR1) were obtained from the Center for Biomedical Inventions, University of Texas Southwestern Medical School and from Abnova Corporation (Taipei, Taiwan, ROC). Flag antibody was from Sigma-Aldrich (St. Louis, MO).
Cell Culture and Assays
HUVECs (Clonetics, Biowhittaker, Inc., Walkersville, MD) were cultured and transduced with retroviruses carrying various constructs as previously described (23) . HMDVECs were isolated from newborn foreskins (35) and were cultured in EBM medium. At 80% confluence, HUVEC and HMDVEC were incubated in 0.1% fetal bovine serum -containing EBM medium for 24 hours and then treated with VEGF-A 165 (10 ng/mL) for different times and subjected to proliferation assays as previously described (23) .
Reverse Transcription-PCR Analyses
RNA was isolated from HUVEC that had been serumstarved for 24 hours and stimulated with 10 ng/mL of VEGF-A for the times indicated. RT-PCR with isoform-specific primers was carried out as described (17) . Glyceraldehyde-3-phosphate dehydrogenase served as a control for equal RNA loading. RT-PCR products were analyzed on 4% agarose gels. Experiments were repeated thrice.
In vivo Angiogenesis Models
Female, 4-to 5-week-old nu/nu mice (NIH) were injected i.d. in ear skin with 1 Â 10 8 plaque-forming units of adenoviral vectors expressing either mouse VEGF-A 164 (AdmVEGF-A 164 ) or, as a control, Ad-LacZ (22) . MOT cells were maintained by i.p. passage in C3H/HeJ mice and 10 6 cells were injected i.p. for growth in ascites form as previously described (36) . Ears and mesenteries were homogenized in T-PER tissue protein extraction reagent (Pierce Biotechnology, Inc. Rockford, IL) or in RNA extraction buffer (Qiagen, Inc., Valencia, CA). Equal amounts of protein were subjected to immunoblotting using the mDSCR1 antibody. RNA was isolated and subjected to RT-PCR with DSCR1-1L-or DSCR1-4 -specific primers. Experiments were repeated thrice.
Human Ovarian Carcinomas
Tumors were obtained at the time of surgery and were fixed in 4% paraformaldehyde, embedded in OCT compound and prepared for immunohistochemistry (see below). These experiments were carried out according to a protocol approved by the hospital's Committee on Clinical Investigation.
Immunohistochemistry
Implanted Matrigel plugs were dissected free, fixed in 4% paraformaldehyde for 4 hours, changed to 30% sucrose overnight, and embedded in OCT compound. Frozen sections were then blocked with 5% goat serum and stained with the following primary antibodies at room temperature for 1 hour: rat anti-mCD31 antibody (1:50 dilution; BD Biosciences, PharMingen), mouse anti-hCD31 (1:100 dilution, Dako), or mouse antihDSCR1-1L, mouse anti-hDSCR1-4, mouse anti-mDSCR1, all at 1:100 dilution (Center for Biomedical Inventions, University of Texas Southwestern Medical School). Sections were then washed thrice with PBS and incubated for 1 hour with appropriate secondary antibodies: biotinylated polyclonal antirat IgG antibody (1:500 dilution) or biotinylated polyclonal antimouse IgG antibody (1:200 dilution; Vector Laboratories, Inc. Burlingame, CA). Sections were then washed thrice with PBS, reacted with the ABC peroxidase kit (Vector Laboratories) at room temperature for 45 minutes, and washed twice with PBS prior to mounting for light microscopy and photography.
Cloning and Expression of DSCR1 Isoforms and siRNAs DSCR1 isoforms were cloned by RT-PCR using RNA isolated from HUVEC cultured for 1 hour with 10 ng/mL of VEGF-A 165 . The 5 ¶ primers are listed below: DSCR1-1, ATGGAGGAGG TGGACCTGCAGG; DSCR1-1L, CTGATG-GAGGACGGCGTGGCCGG; DSCR1-3, ATGGTGTATGC CAAATTTGAGTCC; DSCR1-4, ATGCATTTTAGAAACTT-TAACTAC. The 3 ¶ primer was TCAGCTG AGGTGGATCG-GCGTGTAC. The identities of the PCR fragments were confirmed by DNA sequencing. The cDNAs were fused in-frame to the Flag sequence, cloned into the retroviral vector pMMP, and overexpressed in HUVEC as described previously (23) .
Recently, a new vector system, pSUPER-retro, was used to direct the synthesis of siRNAs in mammalian cells. Sequence-specific siRNAs destroy the endogenous mRNAs that match the siRNA sequence, thus inhibiting the expression of their cognate protein (37) . siRNAs were designed with the software from OligoEngine, Co. (Seattle, WA), cloned into pSUPER-retro vector (OligoEngine), and expressed in HUVEC. The D1Si and D4Si sequences were GCTTCATT-GACTGCGAGA and CCAGGGCCAAATTTGAGTC, respectively. Neg-Si is the scrambled sequence of D4Si. The Neg-Si is GAACAAATACGCGTGTGTC.
Matrigel Angiogenesis Assays
Matrigel angiogenesis assays were carried out as described (25) . SKMEL/VEGF cells (1 Â 10 7 ), alone or mixed with 1 Â 10 7 of PT67 cells infected with retroviruses expressing various full-length DSCR1 or LacZ cDNAs or DSCR1 isoformspecific siRNAs were suspended in 0.5 mL of growth factorreduced Matrigel (BD Biosciences, Bedford, MA) and injected s.c. into nu/nu mice. Tissues were harvested, photographed, and fixed with 4% paraformaldehyde for immunohistochemistry. In some experiments, the KDR inhibitor SU1498 (Calbiochem, San Diego, CA) or the calcineurin inhibitor, cyclosporine A (Sigma), was incorporated into Matrigel plugs (40 Ag/mL Matrigel) and was also injected i.p. daily (1 mg/kg) after Matrigel implantation. Each experiment was replicated on eight mice.
Quantitative Analysis of Plasma Volumes in Matrigel Assays
These assays were carried out as described (25) . Mice (four per group) implanted with various cell combinations in Matrigel were anesthetized with Avertin (tribromoethanol, 200 mg/kg) and injected i.v. via the tail vein with 0.2 mL of Evan's blue dye (5 mg/mL in saline). After 5 minutes, blood was collected in heparin by cardiac puncture and centrifuged at 14,000 rpm for 10 minutes to obtain platelet-poor plasma which was diluted in formamide for the measurement of Evan's blue dye concentration. Animals were euthanized by carbon dioxide narcosis and Matrigel plugs were dissected free by cautery to prevent blood loss, weighed, and extracted with 2 mL of formamide at room temperature for 3 days. Dye in plasma or extracted from Matrigels was measured at 620 nmol/L in a Thermo Max microplate reader (Molecular Devices, Menlo Park, CA) using Softmax 881 software. Standard curves were generated by the measurement of serial dilutions of Evan's blue dye in formamide (Ag/mL). Intravascular plasma volumes (AL/g Matrigel) were calculated on the basis of Evan's blue dye concentrations in blood plasma to provide an absolute measure of the volume of plasma in the vascular bed.
NFAT Targeted Promoter Luciferase Assay
HUVEC transduced with various constructs were seeded in 12-well plates at 1 Â 10 6 cells/well. Twenty hours later, cells were transfected with NFAT-targeted promoter-luciferase plasmid (pGL3 NFAT-Luc) and control luciferase plasmid (pRL-Tk-Luc) with FuGENE6 transfection reagent (Roche Diagnostics, Indianapolis, IN). Cells were washed twice with PBS. Two microliters of Fugene were added directly to 50 AL of OPTI-MEM1 medium and incubated at room temperature for 5 minutes. NFAT-luc plasmid (0.75 Ag) and pRL-Tk (0.15 Ag) were added to the mixture and incubated at room temperature for 15 minutes, and then added to cells with 300 AL of medium. Twenty-four hours later, cells were changed to EBM medium with 0.1% fetal bovine serum. After 24 hours, cells were stimulated with 10 ng/mL of VEGF-A 165 for 6 hours. Cells were washed twice with PBS and incubated with 120 AL of passive buffer from a dual-luciferase reporter Assay system (Promega, Madison, WI) at room temperature until cells were dissolved. Luciferase activity was assayed according to the manufacturer's protocol.
Animal Welfare
All animal experiments were done in compliance with the Beth Israel Deaconess Medical Center's Animal Care and Use Committee.
Statistics
ANOVA and the Tukey-Kramer multiple comparisons test were used to determine statistical significance.
